| Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non–small-cell lung cancer M Fukuoka, S Yano, G Giaccone, T Tamura, K Nakagawa, JY Douillard, ... Journal of clinical oncology 21 (12), 2237-2246, 2003 | 3962 | 2003 |
| Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group JP Pignon, H Tribodet, GV Scagliotti, JY Douillard, FA Shepherd, ... Journal of clinical oncology 26 (21), 3552-3559, 2008 | 2880 | 2008 |
| Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer JY Douillard, KS Oliner, S Siena, J Tabernero, R Burkes, M Barugel, ... New England Journal of Medicine 369 (11), 1023-1034, 2013 | 2620 | 2013 |
| Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with … JY Douillard, S Siena, J Cassidy, J Tabernero, R Burkes, M Barugel, ... Journal of clinical oncology 28 (31), 4697-4705, 2010 | 2226 | 2010 |
| Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB–IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist … JY Douillard, R Rosell, M De Lena, F Carpagnano, R Ramlau, ... The lancet oncology 7 (9), 719-727, 2006 | 2013 | 2006 |
| Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial ES Kim, V Hirsh, T Mok, MA Socinski, R Gervais, YL Wu, LY Li, ... The Lancet 372 (9652), 1809-1818, 2008 | 1751 | 2008 |
| Phase II study of sorafenib in patients with advanced hepatocellular carcinoma GK Abou-Alfa, L Schwartz, S Ricci, D Amadori, A Santoro, A Figer, ... Journal of clinical oncology 24 (26), 4293-4300, 2006 | 1565 | 2006 |
| Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma S Negrier, B Escudier, C Lasset, JY Douillard, J Savary, C Chevreau, ... New England Journal of Medicine 338 (18), 1272-1278, 1998 | 1218 | 1998 |
| Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter … T Le Chevalier, D Brisgand, JY Douillard, JL Pujol, V Alberola, A Monnier, ... Journal of Clinical Oncology 12 (2), 360-367, 1994 | 1152 | 1994 |
| Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised … M Reck, R Kaiser, A Mellemgaard, JY Douillard, S Orlov, M Krzakowski, ... The lancet oncology 15 (2), 143-155, 2014 | 1100 | 2014 |
| Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients T Le Chevalier, R Arriagada, E Quoix, P Ruffle, M Martin, M Tarayre, ... JNCI: Journal of the National Cancer Institute 83 (6), 417-423, 1991 | 1058 | 1991 |
| Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer JY Douillard, S Siena, J Cassidy, J Tabernero, R Burkes, M Barugel, ... Annals of Oncology 25 (7), 1346-1355, 2014 | 645 | 2014 |
| Molecular predictors of outcome with gefitinib and docetaxel in previously treated non–small-cell lung cancer: data from the randomized phase III INTEREST trial JY Douillard, FA Shepherd, V Hirsh, T Mok, MA Socinski, R Gervais, ... Journal of clinical oncology 28 (5), 744-752, 2010 | 627 | 2010 |
| 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up J Vansteenkiste, L Crino, C Dooms, JY Douillard, C Faivre-Finn, E Lim, ... Annals of Oncology 25 (8), 1462-1474, 2014 | 554 | 2014 |
| Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status JY Douillard, G Ostoros, M Cobo, T Ciuleanu, R Cole, G McWalter, ... Journal of Thoracic Oncology 9 (9), 1345-1353, 2014 | 520 | 2014 |
| Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind … JF Vansteenkiste, BC Cho, T Vanakesa, T De Pas, M Zielinski, MS Kim, ... The lancet oncology 17 (6), 822-835, 2016 | 481 | 2016 |
| First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study JY Douillard, G Ostoros, M Cobo, T Ciuleanu, R McCormack, A Webster, ... British journal of cancer 110 (1), 55-62, 2014 | 465 | 2014 |
| Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non–small-cell lung cancer treated with adjuvant chemotherapy … JY Douillard, R Rosell, M De Lena, M Riggi, P Hurteloup, MA Mahe, ... International Journal of Radiation Oncology* Biology* Physics 72 (3), 695-701, 2008 | 454 | 2008 |
| ERCC1 isoform expression and DNA repair in non–small-cell lung cancer L Friboulet, KA Olaussen, JP Pignon, FA Shepherd, MS Tsao, S Graziano, ... New England Journal of Medicine 368 (12), 1101-1110, 2013 | 432 | 2013 |
| Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial T Conroy, MP Galais, JL Raoul, O Bouché, S Gourgou-Bourgade, ... The lancet oncology 15 (3), 305-314, 2014 | 425 | 2014 |
